The Myth of the Low-Hanging Fruit
Mar 5, 2012, 00:10 AM
by
Michael Croft
Forbes | The "low-hanging fruit" that fueled biotech and pharma in the past is a myth, says John LaMattina. R&D isn't emerging from a golden age of discovery; research has always been hard and the blockbusters of yesterday came at the expense of "spectacular failures."
March 5, 2012 | The "low-hanging fruit" that fueled biotech and pharma in the past is a myth, says John LaMattina. R&D isn't emerging from a golden age of discovery; research has always been hard and the blockbusters of yesterday came at the expense of "spectacular failures." The fruit has always been hard to reach, but thanks to expectations of patients, doctors, and payers, the trees are higher than ever. Forbes